No black box warning on record for Voranigo

As of the latest FDA labeling reviewed, Voranigo (VORASIDENIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Voranigo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated. Withhold, reduce the dose or discontinue VORANIGO based on severity. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity : VORANIGO can cause fetal harm. Advise patients of the potential risk to a fetus and to u

No black box warning on record for Voranigo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated. Withhold, reduce the dose or discontinue VORANIGO based on severity. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity : VORANIGO can cause fetal harm. Advise patients of the potential risk to a fetus and to u

Voranigo Black Box Warning

No black box warning on record for Voranigo

Other warnings & precautions

Voranigo Black Box Warning

No black box warning on record for Voranigo

Other warnings & precautions